Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 55c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $57.66 -2.01%
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
SICP, MNSB, CFFI, More
Financial Fact:
Change in value of derivatives: -113.36K
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($1.02), $0.55 worse than the analyst estimate of ($0.47).
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- Freedom Broker Upgrades Kinder Morgan (KMI) to Buy
- Agnico, Barrick, and Newmont fall following broad Freedom Broker downgrades
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
